Pertuzumab (Perjeta) became the first drug to ever be approved by the FDA for use prior to surgery for non-metastatic breast cancer on September 30, 2013. This development further signals a paradigm shift away from chemotherapy and towards targeted therapy – specifically in the now increasingly target-rich environment of HER2-positive breast cancer.
What is Perjeta?
Pertuzumab is a monoclonal antibody, which works by preventing a molecular interaction between the HER2 receptor and other related receptors on the breast cancer cell’s surface. We’ve known about the effectiveness of pertuzumab based on a prior trial with over 800 patients (CLEOPATRA).